The profile of Rescula makes it an ideal adjunctive therapy in glaucoma. About glaucoma Glaucoma is an optic neuropathy where the optic nerve at the back of the eye becomes progressively damaged resulting in first loss of peripheral and then central vision. Glaucoma is more common in those over 50 years of age. A raised pressure in the eye is one of the major risk factors in developing vision loss in glaucoma. Impaired vascular function leading to inadequate retinal blood supply has also been implicated as a cause of visual loss.
Current treatments concentrate on eye drops that lower the pressure inside the eye.
These were reported in approximately ten to twenty-five percent of patients. Rescula has received regulatory approval in USA, Brazil, Argentina, Bolivia, Chile, Colombia, Costa Rica, Czech Republic, Ecuador, Egypt, El Slavador, Guatemala, Hungary, Latvia, Lebanon, Maldives, Malta, Mexico, Pakistan, Panama, Paraguay, Peru, Philippines, Poland, Romania, Russian Federation, Singapore, Sri Lanka, Thailand, Uruguay, Venezuela. In Japan the product is marketed by Fujisawa. Full prescribing information on Rescula is available on request through your local Novartis Ophthalmics offices .